General Dermatology
Eczema
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management

Reimbursement Achievable for Biologics in Psoriasis

September 1, 2003

Article

The January FDA clearance of Biogen Inc.'s Amevive (alefacept) for thetreatment of moderate-to-severe chronic plaque psoriasis officially usheredin the era of biologic treatments for dermatologists. Amgen Inc.'s biologic,Enbrel (etanercept), FDA-cleared for treating psoriatic arthritis, has alsobeen prescribed (off-label) for psoriasis. Amevive, administered by IM injectionor IV infusion in the physician's office, is purchased directly from Biogenby the physician or institution while self-injected Enbrel is purchasedby the patient at the pharmacy.